In an effort to improve outcomes, Dr. Hanscom outlined a structure whereby the many variables of the virus are systematically addressed. The approach, published in SciMedicine Journal, is intended to be used as a foundation for designing clinical trials.
“With the crushing workload, it’s a challenge to get physicians’ attention and consider a different approach,” Dr. Hanscom said.
More research is needed around the dosing and timing of treating COVID-19 patients, according to Dr. Hanscom, as most of the treatments available are “medically proven with minimal or no risk.”
The workgroup highlighted several protocols, including optimizing the body’s defenses with nutrition, vitamins, sleep and exercise; using the body’s own resources by engaging the nervous system to counteract elevated pro-inflammatory cytokines; and then using pharmacological interventions, beginning with minimal risk medications.
Click here to read more on the approach to treating COVID-19 patients.
More articles on spine:
Medtronic Q1 spine revenue down 14% to $1.8B; CEO reports ‘faster than expected recovery’
Dr. Richard Berger: Potential for delays makes now ‘the best time to get surgery’
Total Orthopedics Sports & Spine, American Airlines gain EPA approval for COVID-19 surface cleanser
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
